Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Diffuse Intrinsic Pontine Glioma: early-phase trial registry
3 of 6 indexed Recurrent Diffuse Intrinsic Pontine Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recurrent Diffuse Intrinsic Pontine Glioma: 6 US clinical trials tracked, 3 recruiting.
Recurrent Diffuse Intrinsic Pontine Glioma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-diffuse-intrinsic-pontine-glioma
OPEN 3 | RECR 50% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Recurrent Diffuse Intrinsic Pontine Glioma lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Diffuse Intrinsic Pontine Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Diffuse Intrinsic Pontine Glioma is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Diffuse Intrinsic Pontine Glioma research.
National Cancer Institute (NCI) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Diffuse Intrinsic Pontine Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 65 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Recurrent Diffuse Intrinsic Pontine Glioma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
NCT05009992
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
NCT05278208
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT04870944
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
NCT02359565
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
NCT03598244
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
NCT03387020
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Diffuse Intrinsic Pontine Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Diffuse Intrinsic Pontine Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Diffuse Intrinsic Pontine Glioma page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Recurrent Diffuse Intrinsic Pontine Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Diffuse Intrinsic Pontine Glioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Diffuse Intrinsic Pontine Glioma condition card totals 6 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.